Last reviewed · How we verify
Topotecan Hydrochloride Liposomes
Topotecan Hydrochloride Liposomes is a Small molecule drug developed by Gynecologic Oncology Group. It is currently in Phase 1 development. Also known as: Brakiva.
At a glance
| Generic name | Topotecan Hydrochloride Liposomes |
|---|---|
| Also known as | Brakiva |
| Sponsor | Gynecologic Oncology Group |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- 58300-Neutrophil count decreased
- 65800-Platelet count decreased
- Fatigue
- Nausea
- Abdominal Pain
- Anemia
- Constipation
- Vomiting
- Diarrhea
- 43100-Hypokalemia
- 44800-Infections and infestations - Other specify
- Hot Flashes
Key clinical trials
- Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (PHASE2, PHASE3)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (PHASE2)
- MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer (PHASE2)
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (PHASE2, PHASE3)
- A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer (PHASE3)
- A Study of SHR-A1811 in Subjects With Ovarian Cancer (PHASE3)
- Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (PHASE2)
- Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topotecan Hydrochloride Liposomes CI brief — competitive landscape report
- Topotecan Hydrochloride Liposomes updates RSS · CI watch RSS
- Gynecologic Oncology Group portfolio CI
Frequently asked questions about Topotecan Hydrochloride Liposomes
What is Topotecan Hydrochloride Liposomes?
Topotecan Hydrochloride Liposomes is a Small molecule drug developed by Gynecologic Oncology Group.
Who makes Topotecan Hydrochloride Liposomes?
Topotecan Hydrochloride Liposomes is developed by Gynecologic Oncology Group (see full Gynecologic Oncology Group pipeline at /company/gynecologic-oncology-group).
Is Topotecan Hydrochloride Liposomes also known as anything else?
Topotecan Hydrochloride Liposomes is also known as Brakiva.
What development phase is Topotecan Hydrochloride Liposomes in?
Topotecan Hydrochloride Liposomes is in Phase 1.
What are the side effects of Topotecan Hydrochloride Liposomes?
Common side effects of Topotecan Hydrochloride Liposomes include 58300-Neutrophil count decreased, 65800-Platelet count decreased, Fatigue, Nausea, Abdominal Pain, Anemia.
Related
- Manufacturer: Gynecologic Oncology Group — full pipeline
- Also known as: Brakiva